Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops RISC-V processor IP for customizable and energy-efficient computing solutions
Develops automated cell therapy manufacturing platforms
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Pitching T. Rowe Price Investment Management? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room